Detailing the grueling process and levels of determination necessary to go public, David Guyer, CEO for Ophthotech, begins this panel discussion with some of the more trying aspects of going public. Continuing to lead this distinguished panel through a IPO focused conversation, David stresses the importance of timing and perseverance throughout the planning and on the road stages.
David Guyer, MD
Under Dr. Guyer’s leadership, Ophthotech raised more than $350 million in financing from May to September 2013, including a $192 million IPO, a multi-tranched $125 million royalty financing deal with Novo A/S and a $50 million Series C private funding round.
Jeff Hoffman is a Senior Managing Director at Guggenheim Securities, LLC. He has more than 25 years experience in the full range of investment banking activities including financial advisory services, mergers and acquisitions, equity and debt financings, and private equity and venture capital investments.
Dan Myers is the Co-Founder, President, and CEO of Alimera Sciences, Inc. Under Dan’s leadership Alimera has commercially launched ILUVIEN®, Alimera’s lead product, in the US, UK, Germany and Portugal with Marketing Authorizations in an additional 14 countries throughout the EU.
Dr. Nicholas Galakatos is a Co-Founder and Managing Director of Clarus Ventures, a global venture capital firm focused on life science investments. He has been a venture capital investor since 1992, initially at Venrock Associates and then at MPM Capital where he was General Partner.
David E. Redlick
Much of Mr. Redlick’s practice involves companies in the life sciences industry. Chambers and Partners ranks Mr. Redlick in Band 1 in the life sciences: commercial category for both the United States and globally.
Chris, who has over 18 years of equity research experience, joined Stephens in July 2010 as a Managing Director focusing on the medical device and hospital supply sector.